The growing prevalence of cardiovascular disorders has been a pivotal factor in expanding the global atrial fibrillation drugs market size in the last few years. Long considered to be the most common disorder which leads to an irregular heartbeat, atrial fibrillation has now turned into a serious global health concern with respect to death rates and societal costs. According to a study undertaken by Cedars-Sinai Heart Institute and the University of Washington’s highly respected Institute for Health Metrics and Evaluation in 2013, about 33.5 million people worldwide (0.5 percent of the global population) are suffering from atrial fibrillation.
The drugs currently being administered to atrial fibrillation patients have a few prominent shortcomings, including narrow therapeutic windows which can result in unacceptable toxicity, if there is even a minimal imprecision in the dosage. Therefore, patients are required to be closely monitored and have their doses adjusted on a daily basis which is rather cumbersome. In light of these shortcomings, it has been observed there is a renewed emphasis on devising new antiarrhythmic drugs for atrial fibrillation at numerous universities and research institutions across the world. Enumerated below are two prominent instances which demonstrate the direction of the research pertaining to the antiarrhythmic drugs for atrial fibrillation treatment and their role in preventing a wide range of heart rhythm disorders:
Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/3253
- A new pharmacological agent – showing promising results for the prevention of brain injury-induced arrhythmias – has been developed by a research team at the Kuban State Medical University, Russia in 2018. The team turned to the aminoindole derivatives to find for an alternative compound which can demonstrate significant activity in conditions of reduced blood flow to the heart due to obstructed arteries.
- Apparently, the study would not only help in developing new antiarrhythmic drugs for atrial fibrillation but would also assist healthcare professionals in Russia to tackle the disease. To put things in perspective, 3 out of 1,000 people suffer from atrial fibrillation in Russia and the count is anticipated to at least double in the next 3 decades.
- At a research study conducted at the Department of Emergency Medicine at Medical University of Vienna, a new drug named Vernakalant has proved to be considerably more effective than other drugs for treating recent-onset of atrial fibrillation. The outcomes of the study showed that in patients (suffering from no or moderate structural heart disease) with recent onset of atrial fibrillation, Vernakalant had several advantages.
Oral drug therapies such as warfarin represent the basis of anticoagulant oral treatment for patients at a higher risk of thromboembolic events. These therapies are witnessing increased traction in the atrial fibrillation drugs industry landscape in the recent years owing to a significant uptick in the incidences of atrial strokes across the globe. Moreover, the recently updated atrial fibrillation treatment guidelines recommend new oral anticoagulants as the preferred option to warfarin to low the risk of stroke.
Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/3253
Elaborating further on the move, these changes to the atrial treatment guidelines were directed toward the prevailing guidelines formulated in 2014 by the American College of Cardiology, American Heart Association, and Heart Rhythm Society. These guidelines are in favor of the newer class of oral anticoagulants which offer several advantages such as not being impacted by vitamin K levels and eliminating the need for regular blood tests. Needless to mention, such optimistic changes in the administration of drugs would significantly impel the oral atrial fibrillation drugs market size. In fact, according to a research study compiled by Global Market Insights, Inc., oral atrial fibrillation drugs market share is set to register an annual growth rate of 3.1 percent over the estimated timeframe.
Driven by changing dietary habits, increase in sedentary lifestyle and the resultant rise in the prevalence of cardiovascular diseases in the emerging and developed nations alike, the global atrial fibrillation drugs industry is set to grow at an unprecedented pace in the upcoming years. As per reliable estimates, the revenue share of the worldwide atrial fibrillation drugs market is set to exceed a total of USD 17 billion by 2025.